An interventional study of Diagnostic Procedure and Electronic Health Record Review in Thyroid Gland Carcinoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Thyroid Neoplasms with a site in United States — 53 open to participants now, 88 under way, 3 of them phase 3. Thyroid Neoplasms · United States.
Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 2nd largest by planned enrollment of the 231 interventional ones that give a count, is one of 16 that started in 2021, is one of 50 with no phase, reaches primary completion later than 28 of the 82 other live ones, and was the 238th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →53 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States, Mexico
Ages 18+
Kaiser Permanente · Sites in United States
Ages 21–45
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Thomas Hope · Sites in United States
Ages 12+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 120 · Phase 3 10 · Phase 4 5
First in 1977; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,450 is above the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 231 interventional studies, 200 across the 47 observational. Of the 182 that completed or were terminated, 93 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 283 have an industry lead sponsor. The 10 most frequent:
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
City of Hope Medical Center has 1 study filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
26 of the studies in Thyroid Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03099356University of Michigan Rogel Cancer CenterCyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | 2026-12 |
| NCT06220656Dartmouth-Hitchcock Medical CenterTRAIL Study: Feasibility and Pilot | 2026-12 |
| NCT05366881Adela, InccfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | 2026-12-31 |
| NCT06207188Mayo ClinicIdentification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters | 2026-12-31 |
| NCT04916990University of Colorado, DenverImproving Care for Rural Patients With Solid Tumors | 2027-01-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 283 studies in Thyroid Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.
PRIMARY OBJECTIVE:
I. To evaluate the effect of Diagnostic DNA Methylation Signatures (DDMS-2) results (positive predictive value [PPV], negative predictive value [NPV], sensitivity and specificity) on physician decision-making for clinical management of 800 indeterminate thyroid nodules.
SECONDARY OBJECTIVES:
I. To determine sensitivity and specificity, PPV, NPV of DDMS-2 with 1450 needle biopsies including 800 needle biopsies with indeterminate cytopathology.
II. Compare the diagnostic accuracy between DDMS-2 and two currently used diagnostic approaches based on genetic alterations and gene expression within the same prospective cohort of 800 indeterminate needle biopsies.
OUTLINE:
Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.
Procedure: Diagnostic Procedure · Other: Electronic Health Record Review · Procedure: Needle Biopsy
Analysis via DDMS-2
Also known as: Diagnostic Method, Diagnostic Technique, Diagnostic Test
Review of medical records
Undergo needle biopsy
Also known as: Aspiration Biopsy, Puncture Biopsy
Sensitivity of Diagnostic Deoxyribonucleic Acid (DNA) Methylation Signatures (DDMS-2)
The sensitivity of DDMS-2 will be estimated by taking the ratio of the number of true thyroid cancer specimens diagnosed as cancer by DDMS and the total number of thyroid cancer specimens. Will also determine the 95% confidence intervals.
Time frame: Up to 5 years
Specificity of DDMS-2
The specificity will be estimated by taking the ratio of the number of true benign nodules diagnosed as benign by DDMS and the total number of true benign thyroid nodules. Will also determine the 95% confidence intervals.
Time frame: Up to 5 years
Positive predictive value (PPV) of DDMS-2
PPV (number of true thyroid cancer specimens by DDMS / number of thyroid cancers diagnosis by DDMS) will be calculated. Will also determine the 95% confidence intervals.
Time frame: Up to 5 years
Negative predictive value (NPV) of DDMS-2
NPV (number of true benign nodules diagnosed by DDMS/number of benign diagnosis by DDMS) will be calculated. Will also determine the 95% confidence intervals.
Time frame: Up to 5 years
Started Dec 2021 (actual). Primary completion is estimated for Jan 2027, 60 months after the start.
Of 126 non-industry interventional studies with no phase under Thyroid Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 78. This study's planned 60 months is above that.
Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 14 and three quarters within 78.
Start moved once since we started tracking on Sep 25, 2026: Oct 2021 → Dec 2021, on Oct 16, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 5, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.